Bad blood: secrets and lies in a silicon valley startup
Material type:![Text](/opac-tmpl/lib/famfamfam/BK.png)
- 9781509868087
- 338.7681761 CAR
Item type | Current library | Collection | Call number | Copy number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
![]() |
Indian Institute of Management LRC General Stacks | Public Policy & General Management | 338.7681761 CAR (Browse shelf(Opens below)) | 1 | Available | 003398 |
Browsing Indian Institute of Management LRC shelves, Shelving location: General Stacks, Collection: Public Policy & General Management Close shelf browser (Hides shelf browser)
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
||
338.7621 DEL Direct from Dell: strategies that revolutionized an industry | 338.762920973 SLO My years with general motors | 338.76292293092 VAN Elon Musk: how the billionaire CEO of SpaceX and Tesla is shaping our future | 338.7681761 CAR Bad blood: | 338.82 GIL Innovation matters: | 338.88 BEN International business | 338.88 DAN International business |
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.
In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley
There are no comments on this title.